Browse studies

Find your next paid study

3,843 recruiting studies matching your filters

An Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Quarterly Letrozole SIE and Once Daily 2.5 mg Oral Letrozole (Femara®) in Post-Menopausal Women Treated With Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. (SIE-1)

The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus…

Hormone Receptor Positive Early Breast Cancer

Estimated

~$10 – $8,750

Rovi Pharmaceuticals LaboratoriesNCT07401381

Phase 3

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doubl…

Non-squamous Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT06627647

Phase 3

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembroliz…

Non-Small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT06357533

Phase 2

Phase 2 Randomized Study to Assess Use of Androgen Deprivation to Enrich PSMA Expression and Improve Sensitivity of Staging PSMA PET/CT: The EnrichPSMA Trial

This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific me…

Prostate AdenocarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8+1 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07025369

Phase 3

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epider…

Advanced Non-small Cell Lung Cancer, HER2 Mutation

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lym…

Small Cell Lung Cancer

Precise Oncology Interventions in Nutrition and Training (OnPoint)

The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and…

Breast CancerProstate CancerColorectal Cancer+1 more

Estimated

~$10 – $6,250

University of MiamiNCT06534918

Phase 2

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT03899155

Intra-Operative Radiation Therapy (IORT) Using the IntraBeam® System - A Registry Protocol

This registry trial is designed to track the local control rates and side effects of IORT, which will be implemented for women who are suitable partial breast …

Breast Cancer

Estimated

~$10 – $750

Albert Einstein College of MedicineNCT04994067

Phase 2

Phase II Study of Adjuvant Botensilimab in Combination With Balstilimab in Patients With Colorectal Cancer and Persistent Circulating Tumor DNA Following Surgery and Chemotherapy

The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effect…

Colorectal CancerRectal Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07227636

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, ther…

Non Small Cell Lung Cancer

Estimated

~$10 – $1,125

N-Power MedicineNCT07028489

Phase 1

A Prospective Pilot Clinical Trial of Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain

Participants who are experiencing abdominal pain due to having cancer in their pancreas may be eligible for this research study. For this type of pain, doctors…

Pancreatic CancerRetroperitoneal Pain Syndrome

Estimated

~$10 – $6,250

Case Comprehensive Cancer CenterNCT07117032